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The nature and frequency of the major CFTR mutations in the North African population remain unclear, although a small number of
CFTR mutation detection studies have been done in Algeria and Tunisia, showing largely European mutations such as F508del, G542X and
N1303K, albeit at different frequencies, which presumably emerged via population admixture with Caucasians. Some unique mutations were
identified in these populations. This is the first study that includes a genetic and clinical evaluation of CF patients living in Algeria. In order
to offer an effective diagnostic service and to make accurate risk estimates, we decided to identify the CFTR mutations in 81 Algerian
patients. We carried out D-HPLC, chemical-clamp denaturing gradient gel electrophoresis, multiplex amplification analysis of the CFTR
gene and automated direct DNA sequencing. We identified 15 different mutations which account for 58.5% of the CF chromosomes. We
used a quantitative PCR technique (quantitative multiplex PCR short fragment fluorescence analysis) to screen for deletion/duplication in the
27 exons of the gene. Taking advantage of the homogeneity of the sample, we report clinical features of homozygous CF patients. As CFTR
mutations have been detected in males with infertility, 46 unrelated Algerian individuals with obstructive azoospermia were also
investigated.
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Since the cloning of the cystic fibrosis transmembrane
conductance regulator (CFTR) gene [1,2], which is respon-
sible for cystic fibrosis (CF), more than 1300 CF mutations
have been reported by the members of the Cystic Fibrosis
Genetic Analysis Consortium. There are marked variations
in the frequency of some non-F508del CF mutations with
respect to geographical location and ethnic group. In⁎ Corresponding authors. O. Loumi is to be contacted at Faculté des
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Laboratoire de Génétique Moléculaire, 46 rue Félix Le Dantec–29200 Brest,
France.
E-mail addresses: ouridaloumi@yahoo.fr (O. Loumi),
claude.ferec@univ-brest.fr (C. Ferec).
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doi:10.1016/j.jcf.2007.04.004Algeria, no information is available about the incidence of
CF and, in general, there are few data on the molecular basis
of CF in the Maghrib, probably due to underdiagnosis [3–5].
F508del is found on only 20% of the CF chromosomes in
Algeria [6] and Tunisia. Up to now, about 30 other mutations
have been reported, most of which were previously
described in other populations. Still, 3 mutations may be
specific to the Algerian [7–9] population (A141D, L227R,
and N1303H) and 2 to the Tunisian population (T665S and
2766del8).
In order to carry out an effective diagnostic service, we
have undertaken a complete screening of the 27 exons of the
CFTR gene in Algerian CF chromosomes by D-HPLC,
denaturing gradient gel electrophoresis (DGGE) and QMPSF
analysis. Taking advantage of the homogeneity of the sample,
an evaluation of the most important clinical parameters is
presented.ed by Elsevier B.V. All rights reserved.
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2.1. Sample composition
A total of 81 related and unrelated children from Algeria
presenting a reminiscent clinic picture of cystic fibrosis were
investigated. The patients were referred to us by different
paediatric units ofAlgeria. Cystic fibrosis diagnosis was based
on sweat tests: normal values are b40mM; positive values are
N60 mM. Borderline values are between 40 and 60 mM. The
results were considered as being discordant when repeated
sweat chloride analyses yielded inconsistent results. Sweat
tests carried out at the ISSAD HASSANI hospital of Beni-
Messous (Algiers) gave the following results: 36 patients
showed a positive sweat test (with clinical pulmonary and/or
gastrointestinal findings), 19 patients showed a discordant
sweat test and 26 patients a normal sweat test affected by
dilatation of bronchi and chronic obstructive pulmonary and
digestive disease. Forty-six unrelated azoospermia men with
normal FSH values and normal testicular volume were
referred to us by the endocrinology unit of Mustapha Hospital
(Algiers). We had no more clinical information.
2.2. Mutation analysis
Blood samples were collected from the affected children,
their parents and azoospermia men. Genomic DNA was
extracted from peripheral blood leucocytes by standard
methods. All DNA samples were first screened for the
F508del mutation as previously described [10].
The samples of 36 children, without identified CF
mutations were analysed by D-HPLC, DGGE of the entire
coding sequence and flanking intronic sequences as described
elsewhere [11,12,8]. For D-HPLC analysis, we chose a
Touchdown PCR protocol as already described [14] and by
OLA assay [13]. We used a quantitative PCR technique
(quantitative multiplex PCR short fragment fluorescence
analysis) to screen for deletion/duplication in the 27 exons of
the gene [15–19]. In addition to F508del, 30 mutations were
screened in the 19 children with borderline sweat test and in
the 26 children with normal sweat test, by means of the
amplification refractory mutation system (ARMS™) using a
commercial kit allowing the detection of 30 mutations in the
CFTR gene [20] (ELUCIGENE™ CF 30).
Genomic DNA from the 46 obstructive azoospermia men
was screened for 29 mutations by using Luminex™ tech-
nology based on fluorescent detection using a flow
cytometer, microbeads dyed with multiple fluorescent
colours and laser detection [21,22].We also analysed a
DNA variant (the 5T allele) in a noncoding region of CFTR
that causes reduced levels of the normal CFTR protein [23].
2.2.1. QMPSF analysis and molecular characterization of
the genomic rearrangements
In the present study, we used the technique of quantitative
multiplex PCR amplification of short fluorescent fragments(QMPSF) to resolve a significant fraction of previously
uncharacterized CFTR alleles. Mutation detection and
characterization were performed as previously described
[15–19].
2.2.2. Automatic DNA sequencing
Each electrophoretically altered fragment detected by
DGGE, D-HPLC was reamplified from genomic DNA. PCR
products were purified on Microcon 100 columns (Milli-
pore) and sequenced by Sanger dideoxy-mediated chain
termination, using the ABI PRISM™ BigDye™ Terminator
Cycle Sequencing Kit (PE Applied Biosystems) using
walking primers. The sequences of rearranged PCR products
were compared with the CFTR reference genomic sequence
(GenBank Accession Number NT_007933.13 REGION:
42296307y42485805).
3. Results
Initially, the 3-bp deletion that results in deletion of a
phenylalanine residue at position 508 of the CFTR protein
(F508del) was detected on a non-denaturing 12% poly-
acrylamide gel.
3.1. Classic CF (N=36)
The allele frequency of the F508del mutation observed in
the 72 CF chromosomes was 16.7% (12/72) (Table 1).
Among the 60 CF chromosomes carrying an unidentified
mutated allele, 14 different mutations were identified, as
reported in Table 1: N1303K(6/72), 711+1G→T (6/72),
V754M(1/72), 1812−1G→A(2/72), 2183AA/G(3/72),
[4332delTG−621+3A/G](1/72), G542X(1/72), V562I(2/
72), 1609delCA(2/72), 4271delC(1/72), W1282X(3/72),
S977F(1/72), 21Kbdel( 1/72).
Our screening of the entire coding sequence of the CFTR
gene identified 9 DNA sequence variations shown in Table 2.
A female CF patient of Berber origin was a compound
heterozygote V754M/1812−1G→A. She was admitted at the
age of 3 years to the Department of Paediatrics (Ain Taya
Hospital, East Algeria) for bronchiolitis, a high sweat
chloride test (300 mEq/l) and sputum colonized by Pseu-
domonas aeruginosa. The V754M (G to A at position 2392)
mutation has previously been reported to the Cystic Fibrosis
Genetic Analysis Consortium by Roger Mountford and
seems to confer moderate disease when it is associated either
with 1812−1G→A or G542X.
Moreover, we have identified two complex mutations:
R74W–D1270N in the mother of an Algerian F508del
heterozygous CF patient, and none of these variations were
inherited by the child. Using intragenic polymorphisms, we
have confirmed that R74W and D1270N were not inherited
by the F508del heterozygous CF child. This child has
inherited the 2183AA/G maternal mutation which, when
associated with F508del, confers a CF phenotype [24]. As
this has also been reported in Tunisian CF patients [5], and
Table 2
Variants detected in 36 Algerian patients (N=72 chromosomes)
Variants Localisation N %
T854T T→G 2694 Exon 14a 20 27.7
M470V A→G 1540 Exon 10 11 15.2
Q1463Q G→A 4521 Exon 24 9 12.5
1001+11C/T C→T 1001+11 Intron 6b 7 9.7
L997F G→C3123 exon 17a 2 2.7
875+40A/G Intron 6a 2 2.7
5T Intron 8 2 2.7
E528E G→A 1716 Exon 10 2 2.7
P1290P A→G 4002 Exon 20 1 1.3
dup1716+51→61 dup of 11 bp at 1716+51 Intron 10 0 0
N=number of chromosomes.
Table 1
CFTR mutations detected in 36 Algerian patients (N=72 CF chromosomes)
Mutations Substitution nucleotide Substitution amino acid Localisation N % Cum. fr.
hF508del del CTT Del phe 507/508 Exon 10 12 16.7 16.7
N1303K C→G 4041 Asn→Lys 1303 Exon 21 6 8.3 25.0
711+1G→T G→T711+1 MRNA splicing defect Intron 5 6 8.3 33.3
2183AA/G del A2184 Frameshift Exon 13 3 4.2 37.5
A→G 2183
1609delCA delCA Frameshift Exon 10 2 2.8 40.3
1812−1G→A G→A 1812−1 mRNA splicing defect Intron 11 2 2.8 43.1
V562I G→A 1816 Val→Ile 562 Exon 12 2 2.8 45.9
V754M G→A 2392 Val→Met 754 Exon 13 1 1.4 47.3
W1282X G→A 3978 Trp→Stop 1282 Exon 20 3 4.2 51.5
621+3A/Ga A→G 621+3 mRNA splicing defect Intron 4 1 1.4 52.9
4332delTGa delTG4332 Frameshift Exon 23
G542X G→T 1756 Gly→Stop 542 Exon 11 1 1.4 54.3
4271delC del A 4271 Frameshift Exon 23 1 1.4 55.7
S977F C→T 3062 Ser→Phe 97 Exon 16 1 1.4 57.1
21Kb del 21-kb del Del AA E2–E3 1 1.4 58.5
R74W C→T 352 Arg→Trp 74 Exon 3 0 0
D1270N G→A 3940 Asp→Asn 1270 Exon 20 0 0
Total 43 58.5
N=number of chromosomes; Cum. fr.=cumulative frequency.
a Mutations hawked by the same chromosome 7.
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we suggest that this complex mutation should mostly be
classified as mild or benign. This compound heterozygote
mother had an asymptomatic form of the disease. This was
confirmed by two positive sweat tests (85–90 mEq/l).
The second complexmutation was found in one CF patient
with pulmonary insufficiency. During the screening, abnor-
mal profile D-HPLC of his PCR product was identified in
exons 23, 13 and intron 4. The direct sequencing of these re-
gions revealed the following molecular defects: 4332delTG,
2183AA/G and 621+3A→G. In order to establish their
respective transmission to the affected child, we analysed only
the father’s DNA. As the frameshift mutation 2183AA/G was
the only one to be identified in the father’s genotype, we
deduced that the other two (4332delTG+621+3A/G) were on
the same haplotype and transmitted by his mother. These
mutations have been independently reported elsewhere to the
Consortium to be CF alleles, disease-causing mutations.
Additional clinical data including a sweat test for the mother
will be collected in order to exclude a mild or severe CF
phenotype. The 4332delTG (deletion of TG at position 4332)
mutation does not modify any restriction site. It has pre-
viously been reported by Claustres in a CBAVD patient
associated with the R117Hmutation [25] and seems to confer
a CF phenotype when it is associated with 2183AA/G and
621+3A/G mutations in our case.
The 1609delCA allele was only found in the Algerian CF
patient [3,4], who was homozygous for this mutation. This
deletion occurs in the first nucleotide binding fold of the
CFTR gene and creates several termination codons; the
first one is located ten codons downstream of the CA
deletion. All these data indicate that the 1609delCA mutation
is most probably a CF disease mutation.Taking advantage of the homogeneity of the sample, the
genotype–phenotype correlation can then be established. In
our study, we identified 9 homozygous CF patients: four
F508del/F508del, one N1303K/N1303K, two 711+1G→T/
711+1G→T, one 1609delCA/1609delCA and one W1282X/
W1282X. All these patients had pancreatic insufficiency. The
N1303K/N1303K homozygous patient was the 4-year-old
daughter of related parents and presented pancreatic insuffi-
ciency and serious pulmonary disease with P. aeruginosa
colonization. Three positive sweat chloride tests confirmed
the CF diagnosis. The F508del homozygote was the son of
related parents. He had pancreatic exocrine insufficiency,
severe pulmonary disease and a high sweat chloride test. He
died at the age of 11 years. The 1609delA homozygote was a
girl aged 4.5 years from Miliana (west Algeria). She suffered
from chronic cough, respiratory insufficiency and diarrhoea.
The child was hospitalised twice at 7 and 13 months for
treatment of staphylococcal pneumonia. The diagnosis of CF
was confirmed by sweat chloride levels of 140.57 mEq/l.
Table 4
CFTR mutations and variants detected in 46 Algerian obstructive
azoospermia men (N=92 chromosomes)
N % Cum. fr.
Mutations
ΔF508 2 2.17 2.17
N1303K 1 1.08 3.25
711+1G→T 2 2.17 5.43
Variants
1001+11G/T 13 14.13
T854T 18 19.56
5T 8 8.69
N=number of chromosomes; Cum. fr.=cumulative frequency.
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insufficiency and cor pulmonale. The 1609delCA mutation
was therefore the probable cause of the severe CF symptoms
[4].
The duplication of 11 bases [1716+(51→61)] was only
found in the father of a compound heterozygote V562I/S997F
CF patient. The duplication has previously been found in 3
random Algerian individuals [3]. This duplication does not
create a potential splice donor or splice acceptor sequence. All
these data indicate that the dup 1716+(51→61) mutation is
most likely a polymorphism or a variant. At this time we have
no reason to believe that this is a disease mutation.
3.2. Mild CF-like symptoms
Concerning the 26 patients with a normal sweat test
(b40 mM), analyzed by the technique of ARMS™ we
identified the F508del and 711+1G/T mutations (Table 3).
The heterozygous patient for F508del was diagnosed with
bronchial dilatation at 9 years of age. His sweat chloride
concentration was 39 mEq/l. The heterozygous 711+1G/T
child was diagnosed with repeated bronchitis at five months,
with a sweat chloride concentration of 35 mEq/l. On the 19
children with discordant sweat test analyzed also by
ARMS™ technique, one heterozygous F508del was identi-
fied. Only this patient has been analyzed by D-HPLC, which
allowed to reveal after automatic sequencing the variant
L997F. He was diagnosed at 26 months of age with chronic
cough, digestive disease and discordant sweat test (58 mEq/l;
22 mEq/l; 75 mEq/l). Several sequences variants were
identified by DGGE assay (Table 3).
In reference to the previously suggested classification of
the phenotype [26], whereby pancreatic sufficiency is
attributable to the presence of at least mild dominant CF
allele we show that the 711+1G→T mutation is associated
with the pancreatic insufficiency phenotype. The 711+
1G→T homozygous patient, from Tebessa (west of Algeria),
was admitted at the age of 5.5 years to the Department of
Paediatrics at the Bologhine Hospital in Algiers because of
failure to thrive, bronchiolitis and chronic diarrhoea (3–4
greasy stools/day). Laboratory test indicatedKlebsiella pneu-
moniae in a bronchial sample. Diagnosis of CF was con-
firmed by sweat chloride levels of 126, 119 and 168 mEq/l.Table 3
CFTR mutations and variants detected in 19 patients (Na) and 26 patients
(Nb) respectively with discordant and normal sweat test
Na=19 % Nb=26 %
Mutations
ΔF508 1 2.63 1 1.92
711+1G→T 0 0 1 1.92
Variants
1001+11G/T 4 10.53 – –
T854T 9 23.68 – –
L997F 1 2.63 – –This child died at the age of 6 years from respiratory
insufficiency. His younger sister was seen at the age of
3 months for chronic coughing. She had sweat chloride levels
of 302mEq/l and she is homozygous for the 711+1G→T. The
mutation was identified by OLA assay [13].
3.3. Obstructive azoospermia
Among the 46 men with obstructive azoospermia that we
analysed, we identified 3 CFTR mutations by Luminex™
technology and three variants by DGGE (Table 4). Five
patients had one identified CFTR mutation while 41 did not
present any mutation.
Only the 5 heterozygotes have been analysed by D-HPLC
and QMPSF, one of them presented a combination of
sequence variation as F508C, M470V and 1525−61A/G,
classified as polymorphisms in the CFGAC [27].
4. Discussion
In the classic CF group, after the complete analysis of the
CFTR gene by the different mentioned techniques, all the CF
mutations (except 21 kb deletions) are located in 9 exons and
3 introns and account for 58.5% of Algerian CF chromo-
somes. 41.5% of mutations remain to identify after a
complete CFTR exon screen. Compared to the Tunisian
population, the same informativity of alleles was observed
for 5 mutations [5]. The F508del mutation represents 17.9%
of CFTR alleles, while it represents 16.6% in our Algerian
population [5]. This frequency is lower than that observed
for North European populations but is comparable to
reported data for Turkish, Jewish and Tunisian populations
[5]. The N1303K mutation has already been reported to be
significantly more common in Southern European popula-
tions than in Northern European populations (Cystic Fibrosis
Consortium). The 711+1G→T mutations identified in 3
Algerian CF patients was first described with a high
frequency in CF families living in Quebec. To our knowl-
edge, however, no homozygous case has been observed in
this population. It has not been reported in many European
countries except in some CF patients in France in families of
“Arab” extraction, and in Spain. It is the third most common
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and G452X (8.5%). Our data provide additional evidence for
a higher frequency of this splicing mutation in the Maghrib.
This information is of interest in designing the appropriate
strategy for genetic testing of patients in Algeria, and in
European countries where immigration from the Maghrib is
common. Moreover, 2 additional rare mutations have been
identified in an Algerian CF patient.
Surprisingly, none of the defined mutations (R553X,
G551D, 1717−1G→A, G542X), which occur relatively
frequently in exon 11 in Caucasian populations, was
identified in our Algerian population except the G542X
that has been identified once. This was also described in the
Spanish population with a 4.1% frequency. We can consider
it as endemic in Mediterranean countries.
The previously reported 21-kb deletion, which removes
exons 2–3 [32], seems frequent at the Slavic populations.
This last has been found however once in one Algerian CF
patient (1/72) using QMPSF analysis. The 21-kb deletion
seems to confer severe disease when it is associated with the
G542X mutation. Current data show that the CFTRdele2,3
(21 kb) mutation is particularly common in Czech (6.4% of
all CF chromosomes), Russian (5.2%), Belorussian (3.3%),
Austrian (2.6%), German (1.5%), Polish (1.5%), Slovenian
(1.5%), Ukrainian (1.2%), and Slovak patients (1.1%). It has
sporadically been observed in Canada, USA, France, Spain,
and Turkey [32].
The precise phenotypic consequences of the various
CFTR mutations are important to establish for the clinical
prognosis of the patients and genetic counselling of the
families. Since most CFTR mutations are rare, information
about their severity depends on the study of a large number
of cases and/or the analysis of patients that are homozygous
for these mutations. Because of the high rate of consangui-
nity in North African populations, homozygous forms can be
observed even for rare mutations.
The course of the disease in the 5.5-year-old child
homozygous for the 711+1G→T mutation allows us to
assess the clinical features due to this mutation and thus to
establish the genotype–phenotype relationship. It suggests
that this mutation is a severe allele with regard to lung
disease. The greasy diarrhoea further suggests its association
with pancreatic insufficiency. This 711+1G→T mutation
affects the splice donor consensus sequence in intron 5 [9],
resulting in the skipping of exon 5 and the in-frame joining
of exon 4 to exon 6a [33,34]. Although the reading frame
appeared to be preserved in the transcript, a significant
portion of the first membrane-spanning domain would be
deleted from the mutant CFTR polypeptide, if made.
Concerning the compound heterozygote F508del/L997F,
the L997F variant has previously been reported to the
CFGAC by Kabra and Castellani [35]. It was observed in a
5-year-old North Indian boy, heterozygous, born to con-
sanguineous parents migrated from Pakistan. He had a
borderline high sweat chloride value and features highly
suggestive of cystic fibrosis. But in our case the L997F seemsto result in severe disease when associated with F508del. The
incidence of CFTR mutations in children with normal and
discordant sweat chloride levels is unknown. A few
mutations that might be associated with these sweat chloride
values have now been described [36]. In the case of patients
with the negative sweat test we reported the case of two
heterozygote children presenting one of the two mutations
711+1G→Tor F508del and showing pulmonary problems or
bronchial dilatation. This leads us to think, according to the
literature [37], that the presence of one mutation would be a
predisposition to a chronic pulmonary illness. Further, it has
been reported that the heterozygotes for CFTR mutations
would either have some pulmonary problems or be carriers of
a dilatation of bronchi. In this case it would be necessary to
study parents of CF patients to determine the severity and
impact of these chronic pulmonary affections.
Interestingly three of the identified variants (M470V,
T854T and Q1463Q) are frequently informative in our
Algerian families and could be useful for indirect molecular
diagnosis of CF. The Luminex method that detects 29
mutations permitted to have 10.87% of obstructive azoos-
permia men who presented a mutation. For the remaining
89.13%, it would be necessary to complete the analysis by
other techniques, because the mutation detection method
used here does not have 100% sensitivity, only the 5
heterozygotes benefited from an analysis completed by
D-HPLC and QMPSF.
5. Conclusion
In conclusion, to our knowledge, this is the first study that
includes a genetic and clinical evaluation of Algerian CF
patients living in Algeria. The information provided by our
study on the distribution profile of mutations in this sample
of CF Algerian patients is of interest in designing an
appropriate strategy for genetic testing of patients in Algeria
and in Europe countries where immigration from the
Maghrib is common.
The sweat test remains the key test of diagnosis of the
cystic fibrosis; however, one must underline that a normal
sweat test does not exclude the cystic fibrosis.
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